StonvexLoading…
StonvexStonvexStonvexCore line items from CPRX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-08-04 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $156.92M | $149.39M | $588.99M | $436.38M | $287.98M |
Operating Income | Not available | $73.23M | $257.78M | $195.93M | $129.66M |
Net Income | Not available | $63.73M | $214.33M | $161.63M | $52.11M |
EPS (Diluted) | $0.47 | $0.50 | $1.68 | $1.27 | $0.86 |
Total Assets | Not available | $1.15B | $1.10B | $1.05B | $971.91M |
Total Liabilities | Not available | $134.91M | $149.71M | $131.36M | $115.89M |
Cash & Equivalents | Not available | $755.86M | $709.17M | $689.89M | $652.80M |
Free Cash Flow OCF − CapEx | Not available | $59.56M | $208.61M | $163.75M | $131.31M |
Shares Outstanding | Not available | 122.18M | 122.51M | 123.26M | 122.39M |